Zobrazeno 1 - 10
of 50
pro vyhledávání: ''
Publikováno v:
The Journal of Infectious Diseases. 225:1773-1776
Background Limited evidence exists on efficacy and tolerability of quinacrine for nitroimidazole-refractory giardiasis. Methods Nitroimidazole-refractory giardiasis cases, defined as microbiologically (microscopy and/or PCR) confirmed treatment failu
Autor:
Matthew D. Zimmerman, Elise D Pieterman, Han Wang, Lina Keutzer, Ulrika S. H. Simonsson, Aart van der Meijden, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel, Sanne van den Berg
Publikováno v:
J Infect Dis
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Background The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. Methods We compared the efficacy of an all oral DR tuberculosis drug regimen consi
Autor:
Harel Dahari, Michio Imamura, Evan Gorstein, Susan L. Uprichard, Kazuaki Chayama, Swikriti Dasgupta, Masataka Tsuge, Takashi Nakahara, Scott J. Cotler, Alexander Churkin, David Yardeni, Danny Barash, Ohad Etzion
Publikováno v:
J Infect Dis
We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising ef
Autor:
Alexander J. Thompson, Joseph Doyle, Maria Stepanova, Issah Younossi, Leyla de Avila, Zobair M. Younossi
Publikováno v:
The Journal of Infectious Diseases. 217:1033-1043
Background: There is a paucity of patient-reported outcomes (PROs) data for people undergoing hepatitis C virus (HCV) treatment who are treated with opioid substitution therapy (OST) for addiction. Methods: Patients enrolled in phase 3 clinical trial
Autor:
Andrew H. Talal, Emily O. Dumas, Hongtao Zhang, Jennifer King, Andrew J. Ocque, Christophe Hézode, Richard M Rejman, Jiuhong Zha, Gene D. Morse, Barbara M. Bauer, Daniel E. Cohen, Nancy S. Shulman, Danijela Lucic, Jean-Michel Pawlotsky, Gavin Cloherty
Publikováno v:
The Journal of Infectious Diseases. 217:474-482
Background It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. Methods This partially randomized, open-label, phase 2 study en
Autor:
Jacob Lalezari, Amit Khatri, Peter Ruane, Jennifer R. King, Rolando M Viani, Michael S. Saag, Laveeza Bhatti, Roger Trinh, Oluwatoyin Adeyemi, David L. Wyles, Nancy S. Shulman, Yiran B Hu
Publikováno v:
The Journal of Infectious Diseases. 215:599-605
Background Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV
Autor:
Maria Eugenia Valls, Ana Requena-Méndez, Antonio Clavel, Victoria Fumadó, Diana Pou, Encarnación Rubio, Edelweiss Aldasoro, Silvia Lóbez, Jose Muñoz, Begoña Treviño, Joaquim Gascon, Antonio Federico Martínez Montseny, Pilar Goñi, Juan Cabezos
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
JOURNAL OF INFECTIOUS DISEASES
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Recercat. Dipósit de la Recerca de Catalunya
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Universidad de Barcelona
JOURNAL OF INFECTIOUS DISEASES
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Recercat. Dipósit de la Recerca de Catalunya
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Background: There is little evidence regarding the management of refractory giardiasis after treatment with nitroimidazoles. This study estimates the proportion of persistent giardiasis in 3 hospitals in Barcelona, describes associated risk factors a
Autor:
Flavia Luwedde, Veronica Ades, Paul Natureeba, Diane V. Havlir, Albert Plenty, Pius Okong, Julia Mwesigwa, Edwin D. Charlebois, Jane Achan, Tamara D. Clark, Deborah Cohan, Bridget Nzarubara, Moses R. Kamya, Grant Dorsey
Publikováno v:
The Journal of infectious diseases, vol 210, iss 12
Malaria in pregnancy is associated with adverse maternal and neonatal outcomes, such as spontaneous abortions, stillbirth, intrauterine growth restriction, preterm delivery, low birth weight (LBW), maternal anemia, and neonatal death [1]. Human immun
Publikováno v:
The Journal of Infectious Diseases. 208:224-234
(See the editorial commentary by Celum et al on pages 189–91) Oral antiretroviral (ARV) pre-exposure prophylaxis (PrEP) is a new biomedical intervention against human immunodeficiency virus (HIV) transmission with proven efficacy [1–3]. There is
Autor:
Eric S. Daar, Katie R. Mollan, David W. Haas, Gene D. Morse, Paul E. Sax, Camlin Tierney, Margaret A. Fischl, Ann C. Collier, Heather J. Ribaudo
Publikováno v:
The Journal of Infectious Diseases. 207:420-425
The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavire